UPClytics
Alle Fälle anzeigen

UPC APP 8392/2024

·EP2196231: System for ambulatory drug infusion comprising a filling apparatus for flexible containers

Verfahrensdetails
Status
Verfahrensart
Verfahrensantrag
Kategorie
Sonstige prozessuale
Parteien
Kläger
Vertreter: Charlotte Garnitsch (Taylor Wessing); Wim Maas (Taylor Wessing); Alexander Rubusch (Taylor Wessing)
Beklagte
Vertreter: Christof Augenstein (Kather Augenstein); Katharina Brandt (Kather Augenstein); Robert Knaps (Kather Augenstein); Thomas Kronberger (Grünecker Patent- und Rechtsanwälte PartGmbH)
Division
Paris CD
Richter
Technology
Pharmaceutical & Medical
Sprache
Erste Entscheidung
20. Feb. 2024
Entscheidungen
  • 2024-02-20
    Generic application

    Order of the Paris Central Division (judge-rapporteur) granting Roche Diabetes Care GmbH's application for extension of the deadline for filing its defence in a non-infringement declaration action brought by Tandem Diabetes Care (EP 2 196 231). Roche had filed a preliminary objection disputing jurisdiction which had not yet been decided; it argued it would be unreasonable to finalise a defence that might become unnecessary. The court extended the deadline to 8 April 2024, finding the extension was justified to await the preliminary objection decision, particularly given the parallel revocation action pending before the same court.

    Rechtsfragen:Extension of time for filing defence pending preliminary objectionInteraction between preliminary objection proceedings and main defence deadlineParallel revocation action considerations
Dokumente
  • B07D02FA56A2B9665A82CA04377664C5_en.pdf2024-02-20ENGLISH
Tandem Diabetes Care, Inc. v Roche Diabetes Care GmbH — UPC APP 8392/2024 | UPClytics